Document:

Exhibit 4.15

 

Confidential

 

Execution Copy

AGREEMENT

TO

REPAY INDIVIDUAL LOAN

 

THIS AGREEMENT TO
REPAY AN INDIVIDUAL LOAN (the “Agreement”) is entered this 5th day of February, 2020 (the “Effective Date”),
into by and between Inhibikase Therapeutics, Inc., a Delaware corporation (“Corporation”) and Milton H. Werner,
Ph.D., individually a resident of the State of Georgia (“the Individual”).

 

1.            Corporation
Loan.

 

		(a)	The Amount. The Individual will loan the Corporation a principal amount of $245,250. The
date of the funding of such loan is the Loan Issue Date.

 

		(b)	Terms of Repayment. The principal amount of Individual Loan is to be repaid by Corporation,
either in full or in part until paid in full, as the case may be, without demand and in immediately available funds, in lump sum
on the earlier to occur of either (i) sixth (6th) month following the Loan Issue Date or (ii) the date on
which the Corporation has sufficient funds to repay the Individual Loan (together, the “Maturity Date”).

 

		(c)	Interest. From and including the Loan Issue Date to and including the Maturity Date, the
Individual Loan shall bear simple interest at an annual rate of 1.59%, compounded semi-annually. Such interest shall be payable
on the Maturity Date.

 

		(d)	Tender. All payments of principal and interest shall be made in lawful money of the United
States of America and shall be made by Corporation via wire transfer to an account designated by the Individual or, if no account
is so designated, at the Individual’s address set forth in Section 5 or at such other place as the Individual may designate
in writing.

 

		(e)	Right of Prepayment; Allocation. Corporation shall have the right to repay the Individual
Loan at any time during the term hereof without penalty. Any payments received by the Individual hereunder shall be applied as
follows: first, to any costs and expenses due to Individual hereunder; second, to accrued but unpaid interest hereon; and third,
to pay the unpaid principal balance hereunder.

 

    1

     

    

 

Confidential

 

Execution Copy

 

2.            Events
of Default. The occurrence or existence of any one of the following events or conditions
shall constitute an “Event of Default”:

 

(a)            Corporation
shall fail to pay the principal of, or interest on, Individual Loan when the same becomes due and payable in accordance with
the terms hereof and such amount remains unpaid for ten (10) business days after the due date thereof; or

 

(b)            Corporation
makes a general assignment for the benefit of its creditors or applies to any tribunal for the appointment of a trustee or receiver
of a substantial part of the assets of Corporation, or commences any proceedings relating to Corporation under any bankruptcy,
reorganization, arrangement, insolvency, readjustment of debts, dissolution or other liquidation law of any jurisdiction; or any
such application is filed, or any such proceedings are commenced against Corporation and Corporation indicates its consent to such
proceedings, or an order or decree is entered by a court of competent jurisdiction appointing such trustee or receiver, or adjudicating
Corporation bankrupt or insolvent, or approving the petition in any such proceedings, and such order or decree remains in effect
for ninety (90) days.

 

3.            Remedies.
If an Event of Default occurs and is continuing, Individual may, by notice in writing
to Corporation, declare the entire unpaid principal of Individual Loan to be due and payable immediately. The Corporation agrees
to issue a Warrant to purchase the number of shares equal to 150% the value of the loan at an individual share price of $4.87 in
the case of any default. In the Event of a Default, the Warrant will remain in effect even after the loan is repaid.

 

4.            Expenses.
Except as otherwise provided in this Individual Loan, Employee and Corporation shall bear
its own costs incurred in connection with the negotiation, documentation and execution of this Individual Loan, the closing of
the transactions contemplated herein, and any amendment, waiver, consent, supplement or modification hereto.

 

5.            Notices.
All notices, requests, consents and other communications required or permitted under this
Indivual Loan shall be in writing and shall be deemed to have been delivered three (3) days after the date mailed, postage
prepaid, by certified mail, return receipt requested, or on the date personally delivered:

 

	
        If to Corporation, to:

         

        Inhibikase Therapeutics, LLC

        Attn:     Chairman, Board of

        Directors

        3350 Riverwood Parkway, Suite 1900

        Atlanta, GA 30339
	
        If to Individual, to:

         

        Milton H. Werner, PhD

        874 Birds ML SE

        Marietta, GA 30067

 

Individual and Corporation may designate
a different address by notice given in accordance with the foregoing.

 

6.            Individual’s
Representations and Warranties. Individual hereby represents and warrants to
Corporation that the statements contained in this Section are true, correct and complete as of the date of this
Individual Loan: (a) Individual is a resident of the State of Georgia; (b) Individual has full power and authority
(including full corporate power and authority) to execute and deliver this Individual Loan and to perform its
obligations hereunder; (c) this Individual Loan constitutes the valid and legally binding obligation of Corporation,
enforceable in accordance with its terms and conditions; (d) the execution, delivery and performance of this Individual
Loan and all other agreements contemplated hereby have been duly authorized by Corporation; (e) neither the execution
and delivery of this Individual Loan, nor the consummation of the transactions contemplated hereby, will (i) violate any
constitution, statute, regulation, rule, injunction, judgment, order, decree, ruling, charge, or other restriction of any
government, governmental agency, or court to which Individual is subject or any provision of its charter, bylaws, or other
governing documents, (ii) conflict with, result in a breach of, constitute a default under, result in the acceleration
of, create in any party the right to accelerate, terminate, modify, or cancel, or require any notice under any agreement,
contract, lease, license, instrument, or other arrangement to which Individual is a party or by which it is bound or to which
any of its assets is subject, (iii) result in the imposition or creation of a lien upon or with respect to its assets or
(iv) require the prior written consent of any third party.

 

    2

     

    

 

Confidential

 

Execution Copy

 

7.            Waiver
and Agreement. Any provision of this Individual Loan may be amended, waived or modified
upon the written consent of Individual and Corporation.

 

8.            Assignment;
Binding Effect. Corporation shall not be entitled to assign all or any portion of
its performance obligations under this Individual Loan and any attempted assignment hereof shall be void and of no effect. Individual
may assign this Individual Loan and its right to receive payment hereunder. Subject to the preceding sentences, this Individual
Loan shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors, administrators,
successors and assigns.

 

9.            Governing
Law and Waiver of Jury Trial. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF GEORGIA WITHOUT GIVING EFFECT TO CONFLICTS OF LAWS PRINCIPLES. THE PARTIES HERETO WAIVE
ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE, WHETHER ARISING IN CONTRACT, TORT,
OR OTHERWISE BETWEEN THE PARTIES ARISING OUT OF, CONNECTED WITH, RELATED TO, OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED BETWEEN
THEM IN CONNECTION WITH THIS AGREEMENT OR MATTERS RELATED HERETO.

 

10.            Venue. MAKER
HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE JURISDICTION OF THE COURTS OF THE STATE
OF GEORGIA SITTING IN COBB COUNTY AND OF THE UNITED STATES DISTRICT COURT OF THE DISTRICT OF GEORGIA, AND ANY APPELLATE COURT
FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR FOR RECOGNITION OR
ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL
CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH STATE OR, TO THE EXTENT PERMITTED
BY LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING
SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED
BY LAW. NOTHING IN THIS AGREEMENT SHALL AFFECT ANY RIGHT THAT HOLDER MAY OTHERWISE HAVE TO BRING ANY ACTION OR
PROCEEDING RELATING TO THIS AGREEMENT AGAINST MAKER OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION. MAKER AND HOLDER
HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION
WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING
TO THIS AGREEMENT IN ANY COURT REFERRED TO IN THIS SECTION. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE
FULLEST EXTENT PERMITTED BY LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY
SUCH COURT. EACH PARTY TO THIS AGREEMENT IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN
SECTION 5 OF THIS NOTE. NOTHING IN THIS AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY TO THIS AGREEMENT TO SERVE PROCESS
IN ANY OTHER MANNER PERMITTED BY LAW.

 

    3

     

    

 

Confidential

 

Execution Copy

 

	 	 	 	Milton H Werner, PhD, an Individual
	 
	 	 	 	By:	/s/ Milton H. Werner
	 
	ACCEPTED AND AGREED TO:
	 
	Inhibikase Therapeutics, Inc.
	 
	/s/	Elizabeth O’Farrell	 	
	Elizabeth O’Farrell
	Authorized Board Member

 

    4Exhibit 4.16

 

LETTER AGREEMENT TO RESTATED AGREEMENT TO REPAY INDIVIDUAL
LOAN

 

        Reference is made to that certain Restated Agreement to Repay Individual Loan, dated
June 13, 2020 (the “Agreement”), by and between Inhibikase Therapeutics, Inc., a Delaware corporation
(the “Corporation”) and Milton H. Werner, Ph.D. (the “Individual”). Capitalized
terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.

 

On September 11, 2020,
the Corporation is entering into this letter agreement (the “Letter Agreement”) with the Individual in
connection with the initial public offering of the Corporation’s common stock pursuant to an effective registration statement
under the Securities Act of 1933, as amended (the “IPO”). Accordingly, in consideration of the foregoing,
and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned hereby
agree as follows.

 

Notwithstanding anything
to the contrary set forth in the Agreement:

 

1.                 
Modification to Payment Terms. The Corporation and the Individual agree that, in the event that the Corporation consummates
the IPO, no amount of the Individual Loan will become due and payable until the date that is twelve (12) months subsequent to the
date of the IPO.

 

2.                 
No Other Changes. Except as expressly set forth in this Letter Agreement, the Agreement remains in full force and
effect and is hereby ratified and confirmed. Any reference to the Agreement from and after the date hereof shall be deemed and
construed as meaning the Agreement as modified by this Letter Agreement.

 

3.                 
 Miscellaneous. Sections 5, 7, 8, 9 and 10 of the Agreement shall be incorporated herein, except that references
to “this Agreement” in such sections of the Agreement shall be construed to reference this Letter Agreement when incorporated
by reference herein.

 

 

[Remainder
of Page Intentionally Left Blank; Signatures Follow]

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
the parties have executed this Letter Agreement as of the date first written above.

 

	Milton H. Werner, Ph.D., an Individual	 
	 	 
	By:	/s/ Milton H. Werner	 
	 	 	 
	 	 	 
	Inhibikase Therapeutics, Inc.	 
	 	 
	/s/ Elizabeth O’Farrell	 
	Elizabeth O’Farrell	 
	Authorized Board Member

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]